TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9643529
Drug: GMDP solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMDP solution
Study: 7621303
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Pravastatin 20mg/day and Nicotinic acid 1000mg/day)
Study: 3258558
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human calcitonin-gene-related peptide (hCGRP) 2.5 micrograms
Study: 3258558
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human calcitonin-gene-related peptide (hCGRP) 10 micrograms
Study: 3258558
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human calcitonin-gene-related peptide (hCGRP) 25 micrograms
Study: 31584311
Drug: Dried apple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried apple (120 kcal serving, twice daily)
Study: 31584311
Drug: Control snack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control snack (muffin, 120 kcal serving, twice daily)
Study: 24726378
Drug: Microfracture-based cartilage
Normalized name: SHARK CARTILAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microfracture-based cartilage repair treatment
Study: 24198887
Drug: Periodontal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal therapy (scaling & root planing) in Group B
Study: 24198887
Drug: No periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No periodontal treatment in Group A
Study: 27950663
Drug: EGF 50
Normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: EGF 50 mug/ml
Study: 10789889
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 g/kg) administered prior to both encoding and retrieval
Study: 10789889
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered prior to both encoding and retrieval
Study: 10789889
Drug: Alcohol administered
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administered prior to encoding and retrieval
Study: 8918499
Drug: Breast-conservation treatment
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-conservation treatment (lumpectomy) in node-negative trials
Study: 8918499
Drug: Breast-conservation treatment
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-conservation treatment (lumpectomy) in node-positive trials
Study: 24271056
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (tamoxifen followed by exemestane)
Study: 21055087
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole prophylaxis
Study: 16266450
Drug: Prompt fibrinolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt fibrinolytic therapy
Study: 2324541
Drug: Hib conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hib conjugate vaccine (ProHibit)
Study: 371021
Drug: Oxprenolol 160
Normalized name: oxprenolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol 160 mg in a slow-release formulation with cyclopenthiazide 0.25 mg and potassium chloride 600 mg given once daily
Study: 371021
Drug: Methyldopa 250
Normalized name: methyldopa 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa 250 mg 3 times daily
Study: 23425607
Drug: MMRV(new WS)
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV(new WS) vaccine
Study: 22211198
Drug: Radial shock
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial shock wave therapy in addition to physical therapy
Study: 12801243
Drug: Uric acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid (UA) 0.5 g in 250 ml of 0.1% lithium carbonate/4% dextrose vehicle
Study: 11063279
Drug: Intensive multifactorial
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive multifactorial treatment (lifestyle advice, prescription of aspirin and ACE‐inhibitors, protocol‐driven tight control of blood glucose, blood pressure and cholesterol)
Study: 11063279
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (according to current national guidelines)
Study: 9115065
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg) for 45 days
Study: 1492231
Drug: Dose-intensive chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-intensive chemotherapy regimens supported by GM-CSF
Study: 3890909
Drug: Etomidate (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (continuous infusion increasing from 0.01 mg kg‐1 min‐1 to 0.05 mg kg‐1 min‐1 over 50 min)
Study: 28699973
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group focusing on lifestyle changes, physical activities, and nutritional education, with activities occurring monthly in the school's multimedia room or sports court.
Study: 23011712
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg; maximum dose, 20 mg)
Study: 20212252
Drug: Continuous 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous 6-mercaptopurine (6-MP) and weekly methotrexate (MTX)
Study: 20212252
Drug: Intermittent 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent 6-mercaptopurine (100 mg/m(2)/d for 10 days, with 11 days resting) and MTX (200 mg/m(2) every 3 weeks)
Study: 10609427
Drug: Offset control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Offset control over gas inhalation
Study: 10609427
Drug: No offset
Approvals — FDA: no, EMA: no, PMDA: no
Description: No offset control over gas inhalation
Study: 7426219
Drug: Atropine 0.01
Normalized name: atropine 0.0194 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01 mg kg‐1 i.v. (group I)
Study: 7426219
Drug: Gallamine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallamine 0.3 mg kg‐1 i.v. (group II)
Study: 7426219
Drug: Atropine 0.01
Normalized name: atropine 0.0194 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01 mg kg‐1 i.m. and gallamine 0.3 mg kg‐1 i.v. (group III)
Study: 7426219
Drug: Atropine 0.01
Normalized name: atropine 0.0194 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01 mg kg‐1 i.v. and gallamine 0.3 mg kg‐1 i.v. (group IV)
Study: 26435849
Drug: Litramine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Litramine (3 g/day)
Study: 23768279
Drug: Visceral manipulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visceral manipulation (VM) added to standard physiotherapy treatment regimen.
Study: 23768279
Drug: Standard physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physiotherapy treatment regimen (manual therapy, specific exercise, functional exercise prescription).
Study: 21417617
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release liquid form of codeine (69.7 mg every 12 h)
Study: 21417617
Drug: Codeine in
Normalized name: codeine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine in solution (23.2 mg every 4 h)
Study: 18393643
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL prilocaine infiltration
Study: 18393643
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL prilocaine infiltration
Study: 12172339
Drug: Reboxetine 8
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 8 to 10 mg/day
Study: 12172339
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 to 40 mg/day
Study: 10692976
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) and 1000 mg calcium per day (n = 10)
Study: 10692976
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg calcium per day (n = 14)
Study: 10692976
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group, n = 10)
Study: 7476595
Drug: Pantothenic acid
Normalized name: Pantothenic Acid
DrugBank: Pantothenic acid (DB01783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantothenic acid replacement therapy, dosage and duration not specified
Study: 2337215
Drug: Nefopam 20
Normalized name: nefopam 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 20 mg by intramuscular injection 6 hourly for 24 hours
Study: 2337215
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg 12-hourly and placebo injections at 6 and 18 hours
Study: 2337215
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nefopam and diclofenac
Study: 16837136
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheeting (Cica-Care) applied 24h per day for 6 months
Study: 16837136
Drug: Control intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control intervention (daily massage for 15 min)
Study: 16837136
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheeting (Cica-Care)
Study: 7562017
Drug: One-day antibiotic
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day antibiotic prophylaxis (clindamycin and cefonicid)
Study: 7562017
Drug: Three-day antibiotic
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day antibiotic prophylaxis (clindamycin and cefonicid)
Study: 1935632
Drug: CO2‐containing water
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2‐containing water (1400 mg CO2/kg H2O) at 34 degrees C for 20 minutes
Study: 6988950
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg) and tinidazole (2 g)
Study: 25933795
Drug: Varenicline (VAR)
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline (VAR) 1 mg BID
Study: 25933795
Drug: Naltrexone (NTX)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone (NTX) 25 mg QD
Study: 25933795
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of VAR + NTX
Study: 19548064
Drug: Intra-articular hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronate (HA) injections
Study: 11693870
Drug: N,N-diethyl-M-toluamide (DEET)
DrugBank: Diethyltoluamide (DB11282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N,N-diethyl-M-toluamide (DEET) 1.7 g/day
Study: 3300157
Drug: oxandrolone, 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxandrolone, 0.125 mg/kg/day (Group 2)
Study: 3300157
Drug: somatrem, 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: somatrem, 0.125 mg/kg 3 times/week (Group 3)
Study: 3300157
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of somatrem and oxandrolone (Group 4)
Study: 3300157
Drug: somatrem, 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: somatrem, 0.125 mg/kg 3 times/week and oxandrolone, 0.0625 mg/kg/day (after 12-20 months for Groups 1, 2, and 4)
Study: 3300157
Drug: somatrem and
Approvals — FDA: no, EMA: no, PMDA: no
Description: somatrem and combination groups
Study: 31800354
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) 300 mg/day (range 100-600 mg)
Study: 31800354
Drug: Tetrahydrocannabinol (THC)
Normalized name: tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrahydrocannabinol (THC) 10 mg/day (range 5-30 mg)
Study: 25953805
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) for piperacillin, adjusted to achieve 100% fT>MIC
Study: 25953805
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) for piperacillin, adjusted to achieve 50% fT>MIC
Study: 25953805
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) for piperacillin, baseline to after third TDM
Study: 22986930
Drug: High-dose retinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose retinol supplement (25,000 IU retinyl palmitate/day) for up to 16 years
Study: 21839850
Drug: Olodaterol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olodaterol (all doses)
Study: 21839850
Drug: Olodaterol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olodaterol (40 μg)
Study: 18068876
Drug: Candidate vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate vaccine (recombinant protein HIV-1 gp160MN/LAI with or without DC-Chol adjuvant) administered by the nasal or vaginal route
Study: 15199384
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol ester-enriched (PSE) spread (20 g/day)
Study: 11270916
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg/day (increased to 40 mg/day after 2 weeks)
Study: 11270916
Drug: Amitriptyline 75
Normalized name: amitriptyline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 75 mg/day (increased to 150 mg/day after 2 weeks)
Study: 11270916
Drug: Combined lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined lithium and antidepressant therapy (both paroxetine and amitriptyline)
Study: 8119050
Drug: Theophylline concentration
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline concentration of 10 mg/L
Study: 8119050
Drug: Theophylline concentration
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline concentration of 20 mg/L
Study: 27461547
Drug: 14mg nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14mg nicotine patch
Study: 27461547
Drug: placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo patch
Study: 24892144
Drug: Additional controller
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional controller medications
Study: 18724650
Drug: Tretinoin 0.04%
Normalized name: Tretinoin 0.04% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.04% microsphere gel (TMG)
Study: 7533226
Drug: Moxonidine 0.2-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.2-0.4 mg daily
Study: 3280266
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg cefuroxime (single intravenous injection)
Study: 3280266
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg cefuroxime (three doses)
Study: 3280266
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ceftazidime (single intravenous injection)
Study: 3280266
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ceftazidime (three doses)
Study: 27159073
Drug: Emergency Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency Medicine (EM) physicians
Study: 11322176
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg once daily for 4 days
Study: 16522657
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1200 mg b.i.d. the day before surgery and 600 mg b.i.d. after; administered p.o. for 24 h before operation and maintained i.v. for 48 h after operation.
Study: 16522657
Drug: Control (placebo)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (placebo) administered p.o. for 24 h before operation and maintained i.v. for 48 h after operation.
Study: 14653289
Drug: Listerine Original
Normalized name: Listerine Original Antiseptic Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listerine Original [AP] (alcohol‐containing essential oil/phenolic compound mouthrinse)
Study: 14653289
Drug: Oral B
Normalized name: bran ORAL BOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B Sensitive [PF] (phosphoric acid containing fluoride mouthrinse)
Study: 14653289
Drug: Oral B
Normalized name: bran ORAL BOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B Tooth & Gum Care [AF] (alcohol‐containing fluoride mouthrinse)
Study: 14653289
Drug: Oral B
Normalized name: bran ORAL BOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B Tooth & Gum Care Alcohol Free [OF] (alcohol free fluoride mouthrinse)
Study: 30924958
Drug: Family‐based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family‐based Treatment for ARFID (FBT‐ARFID)
Study: 28861202
Drug: Arthroscopically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopically guided suprascapular nerve block and blinded axillary nerve block (10 mL 0.25% ropivacaine)
Study: 28861202
Drug: Blinded suprascapular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded suprascapular nerve block (10 mL 0.25% ropivacaine)
Study: 26513517
Drug: ST +
Normalized name: ST-36
DrugBank: ST-36 (DB17275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST + EX (smoking cessation treatment plus exercise intervention)
Study: 26513517
Drug: ST +
Normalized name: ST-36
DrugBank: ST-36 (DB17275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST + CTRL (smoking cessation treatment plus wellness education control)
Study: 25155146
Drug: Albiglutide 30
Normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide 30 mg subcutaneous once weekly
Study: 20444749
Drug: Golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 100 mg plus placebo (group 2)
Study: 20444749
Drug: Golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 50 mg plus methotrexate (group 3)
Study: 20444749
Drug: Golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 100 mg plus methotrexate (group 4)
Study: 17383857
Drug: Lamotrigine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (up to 200 mg/day)
Study: 16274377
Drug: Green Prescription
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green Prescription physical activity counseling program
Study: 12087138
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of lansoprazole daily
Study: 8551824
Drug: Octreotide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (50 micrograms intravenous bolus injection followed by intravenous infusion at 50 micrograms per h for 5 days) plus endoscopic variceal ligation
Study: 2182204
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg.kg‐1/hr with alfentanil infusion
Study: 2182204
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg.kg‐1/hr with alfentanil infusion
Study: 2182204
Drug: Propofol 4
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 4 mg.kg‐1/hr with alfentanil infusion
Study: 23746674
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation (CRT)
Study: 19453961
Drug: Gabapentin (600-1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (600-1,800 mg per day)
Study: 17404825
Drug: Intensified LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified LDL-C lowering therapy with ezetimibe
Study: 17404825
Drug: HDL-C raising
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDL-C raising therapy with extended-release niacin
Study: 14697441
Drug: Pentoxifylline (Ptx)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (Ptx) 400 mg, 3 times daily during radiotherapy
Study: 9404250
Drug: Diltiazem 180
Normalized name: diltiazem 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 180 mg and trimetazidine 60 mg
Study: 3500642
Drug: Nabumetone (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (1,000 mg daily)
Study: 28088674
Drug: Web‐based computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web‐based computer intervention targeting substance use and treatment initiation
Study: 16782926
Drug: Very accelerated
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very accelerated radiation therapy (62 to 64 Gy in 31 to 32 fractions of 2 Gy over 22 to 23 days)
Study: 16782926
Drug: Conventional radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional radiation therapy (70 Gy in 7 weeks, 35 fractions of 2 Gy over 49 days)
Study: 16782926
Drug: Very accelerated
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very accelerated radiation therapy
Study: 21353749
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (7.7±3.9 mg per day)